GSK 445A

Drug Profile

GSK 445A

Alternative Names: GSK445A; IngB satbilized - GlaxoSmithKline; Ingenol-B stabilized - GlaxoSmithKline

Latest Information Update: 28 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-infectives; Ingenols; Macrocyclic compounds; Small molecules
  • Mechanism of Action Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 13 Feb 2017 Preclinical trials in HIV infections in United Kingdom before February 2017
  • 13 Feb 2017 Pharmacodynamics data and adverse events from preclinical studies in HIV infections presented at the 24th Conference on Retroviruses and Opportunistic Infection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top